# Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

> **NCT03735446** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Prexasertib
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03735446
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-18
- **Primary completion:** 2019-03-29
- **Final completion:** 2019-03-29
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2019-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03735446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03735446, "Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03735446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*